MyFinsight
Home
Blog
About
Proceeds from issuance of
debt
$1,625K
(-83.15%↓ Y/Y)
Proceeds from issuance of
preferred stock
$1,105K
Proceeds from issuance of
warrants
$995K
(-41.44%↓ Y/Y)
something is missing
$487K
Proceeds from issuance of
common stock
$291K
(-16.14%↓ Y/Y)
Net cash provided by
financing activities
$3,228K
(-71.83%↓ Y/Y)
Canceled cashflow
$1,275K
Net (decrease)
increase in cash and cash...
-$336K
(81.92%↑ Y/Y)
Canceled cashflow
$3,228K
Accounts payable
$950K
(56.25%↑ Y/Y)
Accrued expenses
$929K
(831.50%↑ Y/Y)
Depreciation and
amortization
$511K
(5.80%↑ Y/Y)
Accounts receivable
-$331K
(-223.05%↓ Y/Y)
Contract liability
$88K
(117.32%↑ Y/Y)
Fair value of common
stock issued for...
$72K
Stock-based compensation
expense
$50K
(-91.06%↓ Y/Y)
Operating lease
liabilities, net
$49K
(173.13%↑ Y/Y)
Reduction of debt
liability
$814K
Proceeds from exercise of
warrants
-$447K
(-126.31%↓ Y/Y)
Payments for finance
lease liability
$14K
Net cash used in
operating activities
-$3,148K
(56.82%↑ Y/Y)
Canceled cashflow
$2,980K
Net cash used in
investing activities
-$416K
(93.10%↑ Y/Y)
Net loss
-$5,523K
(37.78%↑ Y/Y)
Other liabilities
-$386K
(-159.75%↓ Y/Y)
Prepaid expenses and
other current assets
$61K
(162.24%↑ Y/Y)
Deposits and other
$18K
(128.13%↑ Y/Y)
Acquisitions of property and
equipment
$416K
(-53.42%↓ Y/Y)
Back
Back
Cash Flow
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)
source: myfinsight.com